159675-85-1

Basic information

• Product Name: Benzoic acid, 4-(2-carboxy-1-propenyl)-, 1-(1,1-dimethylethyl) ester, (E)- (9CI)
• Synonyms: Benzoic acid, 4-(2-carboxy-1-propenyl)-, 1-(1,1-dimethylethyl) ester, (E)- (9CI)
• CAS NO: 159675-85-1
• Molecular Formula: C₁₅H₁₈O₄
• Molecular Weight: 263.30896
• Product Categories: ACIDHALIDE
• Mol File: 159675-85-1.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 400.2±28.0 °C(Predicted)
• Appearance: /
• Density: 1.146±0.06 g/cm3(Predicted)
• PKA: 4.66±0.10(Predicted)
• CAS DataBase Reference: Benzoic acid, 4-(2-carboxy-1-propenyl)-, 1-(1,1-dimethylethyl) ester, (E)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(2-carboxy-1-propenyl)-, 1-(1,1-dimethylethyl) ester, (E)- (9CI)(159675-85-1)
• EPA Substance Registry System: Benzoic acid, 4-(2-carboxy-1-propenyl)-, 1-(1,1-dimethylethyl) ester, (E)- (9CI)(159675-85-1)

Safety Data

• Hazardous Substances Data: 159675-85-1(Hazardous Substances Data)

Downstream Products

• 192637-02-8 (E)-5-[(E)-3-(4-Carboxy-phenyl)-2-methyl-acryloylamino]-5-ethoxycarbonyl-hex-2-enedioic acid diethyl ester 
• 192637-00-6 4-{(E)-2-[(R)-1-Ethoxycarbonyl-2-((E)-3-ethoxycarbonyl-allylsulfanyl)-ethylcarbamoyl]-propenyl}-benzoic acid 
• 192636-98-9 (E)-5-[(E)-3-(4-tert-Butoxycarbonyl-phenyl)-2-methyl-acryloylamino]-5-ethoxycarbonyl-hex-2-enedioic acid diethyl ester 
• 192636-97-8 4-{(E)-2-[(R)-1-Ethoxycarbonyl-2-((E)-3-ethoxycarbonyl-allylsulfanyl)-ethylcarbamoyl]-propenyl}-benzoic acid tert-butyl ester 

Relevant articles and documents

New serine protease inhibitors with leukotriene B4 (LTB4) receptor binding affinity

A series of new trypsin-like serine protease inhibitors, 1, 2 and 7-23, containing amidinobenzene moiety was found to show potent LTB4-receptor affinity. Among them, compounds 1 and 2 were found to be LTB4 receptor antagonists based on an inhibition assay of human polymorphonuclear neutrophil (PMN) intracellular calcium mobilization induced by LTB4. Compounds 1 and 2, which satisfy the reported structural requirements for good oral activity, are expected to show a balanced dual mode of action, i.e., protease inhibitory activity and LTB4 receptor antagonist activity, in vivo.